ESCAPE; 40% in EXTEND-IA; 36% in SWIFT PRIME; and 28% in REVASCAT. These results are valid for patients receiving IV thrombolysis before the thrombectomy. For the first time in the world of acute ischemic stroke, the mortality was significantly reduced in ESCAPE (10% against 19%, p < 0.05). In addition, subgroup analyses of MR CLEAN and ESCAPE trials demonstrated that the benefit of thrombectomy remained among patients older than 80 years old and with various NIHSS thresholds, as well as among patients with tandem occlusions in ESCAPE and REVASCAT. However, rapid management of brain infarction remains mandatory, requiring the involvement of all healthcare stakeholders, as IV thrombolysis, stent retriever thrombectomy should be performed as soon as possible. In fact, in MR CLEAN and EXTEND-IA, the delay between the imaging and the femoral puncture was 60 min and the delay between the imaging and the first stent deployment was 90 min in ESCAPE. In SWIFT PRIME, the delay between the imaging and the femoral puncture was 90 min. These data highlight the importance of minimizing time to recanalization from the pre-hospital stage to the endovascular suite. In addition, it is suggested that these excellent results were obtained by the fact that thrombectomy procedures were performed at relatively highvolume centres, as reported on consensus statement of ESO, ESMINT and ESNR (ESO-Karolinska Stroke Update 2014). This procedure should be realized by a neurointerventionist with threshold number of cases per year to guarantee the safety and efficacy of the thrombectomy. Thus, there is a need for a centralization of thrombectomy procedure and eligible patients should be transferred early to these interventional neuroradiology centres. Interestingly, the addition of intra-arterial treatment therapy compared with standard treatment 1 DHU IRIS, Department of Interventional Neuroradiology, Bron, France alone yielded a lifetime gain of 0.7 QALY for an additional cost of US$9911, which resulted in a cost of US$14,137 per QALY. 10 These findings suggest that there is a strong societal rationale for investment in intra-arterial treatment systems of care.
In conclusion, a new therapeutic era is now opening since it is now clear that stent retriever thrombectomy, in combination with IV thrombolysis, significantly increases neurological recovery at 3 months. These results validate thrombectomy in combination with IV thrombolysis as the new standard treatment of acute ischemic stroke with proximal arterial occlusion within 6 h. Each eligible patient will be able to benefit from this new brain revascularization technique in the shortest possible time, which will require a reorganization of care pathways and strengthening teams of interventional neuroradiologists. 
